Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.On Wednesday, Eli Lilly And Co. (NYSE:LLY) announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
禮來（紐交所:LLY）週三宣佈投資45億美元，建立愛文思控股醫藥製造基地，這將是一家新型先進製造和研發藥品的中心。
As the company inches closer to becoming the first pharma company in the $1 trillion club, it aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.
作爲公司距離成爲萬億美元俱樂部中的第一家藥品公司越來越近，它旨在通過超越競爭對手，鞏固自己作爲美國前十大最有價值公司之一的地位。
In a report, Eli Lilly said it plans to reinvest its revenues into R&D, aiming to escape the pharmaceutical industry's traditional boom-and-bust cycle.
據報道，禮來表示計劃將收入重新投資於研發，以擺脫藥品行業傳統的繁榮與蕭條循環。
The company says the new facility will allow Lilly to research new ways of producing medicines while scaling up the manufacturing of medicines for clinical trials.
公司表示，新設施將使禮來得以研究生產藥品的新方法，並將其擴大到用於臨床試驗的藥品製造規模。
Also Read: Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market.
另請參閱：禮來早期阿爾茨海默病治療多納莫莫（Donanemab）獲得日本批准，其第二大市場。
The Medicine Foundry will be the first-ever facility of its kind to combine research and manufacturing in a single location. It will be located in Indiana's LEAP Research and Innovation District in Lebanon, Indiana, and will expand the company's investment there to more than $13 billion.
醫藥研究中心將是第一個將研究和製造結合在同一地點的設施，它將位於印第安納州黎巴嫩的LEAP研究和創新區，將使公司在該地區的投資擴大到130億美元以上。
This new facility will add to Lilly's previous manufacturing commitments in Lebanon, which include a $2.1 billion investment announced in May 2022 to expand its network for active ingredients and new modalities, such as genetic medicines.
這一新設施將補充禮來此前在黎巴嫩的製造承諾，包括2022年5月宣佈的21億美元投資，以擴大其活性成分和新模式（如基因藥品）網絡。
In April 2023, the company announced an additional $1.6 billion investment.
2023年4月，公司宣佈再投資16億美元。
In May 2024, Lilly announced an additional $5.3 billion commitment to enhance its capacity to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines, marking the largest single investment in active pharmaceutical ingredients production in U.S. history.
2024年5月，禮來公司宣佈再投資53億美元，以增強其用於生產最新糖尿病和肥胖藥物活性藥品的能力，這標誌着美國曆史上對活性藥品生產的最大單筆投資。
Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020. It is trying to stay ahead of its close competitor, Novo Nordisk A/S (NYSE:NVO).
該設施計劃於2027年底投入使用，將使禮來公司自2020年以來在美國的總資本承諾超過230億美元。公司正努力在靠近的競爭對手諾和諾德生物製藥股份有限公司（NYSE：NVO）之前取得領先地位。
Once fully operational, the Medicine Foundry is expected to add 400 full-time jobs.
一旦全面運營，Medicine Foundry預計將增加400個全職工作崗位。
Price Action: At last check on Wednesday, LLY stock was down 0.39% at $881.00 during the premarket session.
股價走勢：最新數據顯示，禮來股票在週三的盤前交易中下跌了0.39%，報881.00美元。
- Eli Lilly Nears First Trillion Dollar Pharma Title, But Investors Caution Amid Sky-High Valuation
- 禮來公司接近首個萬億美元藥品行業市值稱號，但投資者在估值飆升之際表示謹慎。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
